Cargando…

Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant Enterobacteriaceae Infection

BACKGROUND: Infections by Carbapenem-Resistant Enterobacteriaceae (CRE) remain a leading cause of death in critically ill patients. Fosfomycin has been regarded as an alternative therapy for treatment of infections caused by CRE organisms. The purpose of this study is to evaluate clinical outcomes a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanchanasurakit, Sukrit, Santimaleeworagun, Wichai, McPherson, Charles E., Piriyachananusorn, Napacha, Boonsong, Benjawan, Katwilat, Papanin, Saokaew, Surasak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy; The Korean Society for AIDS 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779995/
https://www.ncbi.nlm.nih.gov/pubmed/33124216
http://dx.doi.org/10.3947/ic.2020.52.4.516
_version_ 1783631428700864512
author Kanchanasurakit, Sukrit
Santimaleeworagun, Wichai
McPherson, Charles E.
Piriyachananusorn, Napacha
Boonsong, Benjawan
Katwilat, Papanin
Saokaew, Surasak
author_facet Kanchanasurakit, Sukrit
Santimaleeworagun, Wichai
McPherson, Charles E.
Piriyachananusorn, Napacha
Boonsong, Benjawan
Katwilat, Papanin
Saokaew, Surasak
author_sort Kanchanasurakit, Sukrit
collection PubMed
description BACKGROUND: Infections by Carbapenem-Resistant Enterobacteriaceae (CRE) remain a leading cause of death in critically ill patients. Fosfomycin has been regarded as an alternative therapy for treatment of infections caused by CRE organisms. The purpose of this study is to evaluate clinical outcomes amongst patients with CRE infection who are receiving a fosfomycin dosing regimen using a Monte Carlo simulation and fosfomycin minimum inhibitory concentration (MIC). MATERIALS AND METHODS: Fosfomycin MIC was defined by the E-test method. We used Fosfomycin pharmacokinetic parameters from a previously published study. The percent of the time period in which the drug concentration exceeded the MIC, or %T>MIC, used in this study were determined to be 70% of T>MIC and 100% of T>MIC, respectively. All dosing regimens were estimated for the probability of target attainment using a Monte Carlo simulation. RESULTS: In this study, we found the MIC's of fosfomycin against CRE isolates ranged from 8 mg/L to 96 mg/L. The total daily dose of fosfomycin ranged from 16 - 24 g and was administered utilizing various fosfomycin dosing regimens to achieve the pharmacokinetic/pharmacodynamic (PK/PD) target in pathogens with a MIC of 32 mg/L for 70%T>MIC and a MIC of 12 mg/L for 100%T>MIC, respectively. For the twelve patients who received the recommended fosfomycin dosing regimen, eleven achieved bacterial eradication for a microbiological cure rate of 91%; and of those patients achieving eradication, two died despite having negative cultures for CRE; the one remaining patient had bacterial persistence. The most commonly observed adverse drug reactions were hypernatremia (3 cases) and hypokalemia (3 cases) and acute kidney injury (3 cases). CONCLUSION: Our findings suggest fosfomycin has tended to good efficacy when using dosing regimens that achieve the PK/PD target. Nonetheless, further validation of these regimens in larger populations is needed.
format Online
Article
Text
id pubmed-7779995
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy; The Korean Society for AIDS
record_format MEDLINE/PubMed
spelling pubmed-77799952021-01-05 Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant Enterobacteriaceae Infection Kanchanasurakit, Sukrit Santimaleeworagun, Wichai McPherson, Charles E. Piriyachananusorn, Napacha Boonsong, Benjawan Katwilat, Papanin Saokaew, Surasak Infect Chemother Original Article BACKGROUND: Infections by Carbapenem-Resistant Enterobacteriaceae (CRE) remain a leading cause of death in critically ill patients. Fosfomycin has been regarded as an alternative therapy for treatment of infections caused by CRE organisms. The purpose of this study is to evaluate clinical outcomes amongst patients with CRE infection who are receiving a fosfomycin dosing regimen using a Monte Carlo simulation and fosfomycin minimum inhibitory concentration (MIC). MATERIALS AND METHODS: Fosfomycin MIC was defined by the E-test method. We used Fosfomycin pharmacokinetic parameters from a previously published study. The percent of the time period in which the drug concentration exceeded the MIC, or %T>MIC, used in this study were determined to be 70% of T>MIC and 100% of T>MIC, respectively. All dosing regimens were estimated for the probability of target attainment using a Monte Carlo simulation. RESULTS: In this study, we found the MIC's of fosfomycin against CRE isolates ranged from 8 mg/L to 96 mg/L. The total daily dose of fosfomycin ranged from 16 - 24 g and was administered utilizing various fosfomycin dosing regimens to achieve the pharmacokinetic/pharmacodynamic (PK/PD) target in pathogens with a MIC of 32 mg/L for 70%T>MIC and a MIC of 12 mg/L for 100%T>MIC, respectively. For the twelve patients who received the recommended fosfomycin dosing regimen, eleven achieved bacterial eradication for a microbiological cure rate of 91%; and of those patients achieving eradication, two died despite having negative cultures for CRE; the one remaining patient had bacterial persistence. The most commonly observed adverse drug reactions were hypernatremia (3 cases) and hypokalemia (3 cases) and acute kidney injury (3 cases). CONCLUSION: Our findings suggest fosfomycin has tended to good efficacy when using dosing regimens that achieve the PK/PD target. Nonetheless, further validation of these regimens in larger populations is needed. The Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy; The Korean Society for AIDS 2020-12 2020-10-26 /pmc/articles/PMC7779995/ /pubmed/33124216 http://dx.doi.org/10.3947/ic.2020.52.4.516 Text en Copyright © 2020 by The Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, and The Korean Society for AIDS https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kanchanasurakit, Sukrit
Santimaleeworagun, Wichai
McPherson, Charles E.
Piriyachananusorn, Napacha
Boonsong, Benjawan
Katwilat, Papanin
Saokaew, Surasak
Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant Enterobacteriaceae Infection
title Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant Enterobacteriaceae Infection
title_full Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant Enterobacteriaceae Infection
title_fullStr Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant Enterobacteriaceae Infection
title_full_unstemmed Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant Enterobacteriaceae Infection
title_short Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant Enterobacteriaceae Infection
title_sort fosfomycin dosing regimens based on monte carlo simulation for treated carbapenem-resistant enterobacteriaceae infection
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779995/
https://www.ncbi.nlm.nih.gov/pubmed/33124216
http://dx.doi.org/10.3947/ic.2020.52.4.516
work_keys_str_mv AT kanchanasurakitsukrit fosfomycindosingregimensbasedonmontecarlosimulationfortreatedcarbapenemresistantenterobacteriaceaeinfection
AT santimaleeworagunwichai fosfomycindosingregimensbasedonmontecarlosimulationfortreatedcarbapenemresistantenterobacteriaceaeinfection
AT mcphersoncharlese fosfomycindosingregimensbasedonmontecarlosimulationfortreatedcarbapenemresistantenterobacteriaceaeinfection
AT piriyachananusornnapacha fosfomycindosingregimensbasedonmontecarlosimulationfortreatedcarbapenemresistantenterobacteriaceaeinfection
AT boonsongbenjawan fosfomycindosingregimensbasedonmontecarlosimulationfortreatedcarbapenemresistantenterobacteriaceaeinfection
AT katwilatpapanin fosfomycindosingregimensbasedonmontecarlosimulationfortreatedcarbapenemresistantenterobacteriaceaeinfection
AT saokaewsurasak fosfomycindosingregimensbasedonmontecarlosimulationfortreatedcarbapenemresistantenterobacteriaceaeinfection